首页资讯 Pulse Biosciences宣布任命医学博士David Kenigsberg为电生理学首席医疗官

Pulse Biosciences宣布任命医学博士David Kenigsberg为电生理学首席医疗官

来源：泰然健康网时间：2025年08月26日 01:04

MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology. Andrea Natale, M.D. will become a medical advisor for the company, joining existing advisors Vivek Reddy, M.D.

迈阿密--（商业新闻短讯）--Pulse Biosciences，Inc.（纳斯达克：PLSE），一家利用其新颖专有的纳秒脉冲场消融™（nsPFA™）技术的公司，今天宣布任命医学博士David Kenigsberg为电生理学首席医官。。

and Jacob Koruth, M.D., who altogether will continue to support the development and clinical efforts for the Pulse Biosciences nano-PFA 360 Cardiac Catheter..

和Jacob Koruth医学博士，他们将继续支持Pulse Biosciences nano PFA 360心脏导管的开发和临床工作。。

“I am inspired by the potential of nano-PFA and the unique catheter design of the 360 catheter that is already demonstrating the ability to isolate pulmonary veins with ease and speed,” said Dr. David Kenigsberg, Chief Medical Officer of Electrophysiology of Pulse Biosciences. “I was impressed when I saw the 360 catheter in use and am excited to work with Pulse to deliver robust clinical data with the 360, which I believe will substantially advance the treatment of atrial fibrillation.

Pulse Biosciences电生理学首席医学官David Kenigsberg博士说：“纳米PFA的潜力和360导管的独特导管设计激发了我的灵感，它已经证明了轻松快速地分离肺静脉的能力。”。“当我看到360导管在使用时，我印象深刻，并且很高兴与Pulse合作，用360提供强大的临床数据，我相信这将大大推进心房颤动的治疗。

I look forward to supporting this team through its next phase of clinical development.”.

我期待着通过下一阶段的临床开发来支持这个团队。”。

Dr. Kenigsberg is a practicing cardiac electrophysiologist with a passion for treating atrial fibrillation over his career. He is the founder of Florida Heart Rhythm Specialists and Ft. Lauderdale Heart & Rhythm Surgical Center. He has been the Medical Director of the Electrophysiology Lab at HCA Westside Medical Center in Plantation, Florida, since 2007.

。他是佛罗里达心律专家和劳德代尔堡心律外科中心的创始人。自2007年以来，他一直担任佛罗里达州种植园HCA西区医学中心电生理实验室的医学主任。

He has published numerous scholarly articles in peer-reviewed medical journals. He has advised in the development and has been the primary investigator/co-investigator in a myriad of clinical trials involving ablation tools. Dr. Kenigsberg is a fellow of the American College of Cardiology and the Heart Rhythm Society.

他在同行评审的医学期刊上发表了许多学术文章。他在开发过程中担任过顾问，并且是涉及消融工具的无数临床试验的主要研究者/联合研究者。。

He is the President of the Florida Chapter of the American College of Cardiology and sits on the American College of Cardiology Board of Governors..

他是美国心脏病学会佛罗里达分会会长，也是美国心脏病学会理事会理事。。

“This is an exciting time in electrophysiology as pulsed field ablation technologies are becoming widely adopted and advancing the standard of care. I am excited to support the Pulse team in the clinical efforts for the 360 catheter,” added Dr. Andrea Natale.

Andrea Natale博士补充道：“随着脉冲场消融技术的广泛采用和护理标准的提高，这在电生理学领域是一个令人兴奋的时刻。我很高兴能够支持Pulse团队进行360导管的临床工作。”。

Dr. Andrea Natale is the Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in Austin, Texas, and the National Medical Director of Cardiac Electrophysiology for HCA Healthcare. A dedicated researcher and pioneer, Dr. Andrea Natale focuses on innovative advances in the treatment of atrial fibrillation.

Andrea Natale博士是德克萨斯州奥斯汀圣大卫医学中心德克萨斯心律失常研究所的执行医学主任，也是HCA Healthcare心脏电生理学的国家医学主任。Andrea Natale博士是一位专注的研究人员和先驱，专注于房颤治疗的创新进展。

He has been, and continues to be, involved in many first-in-human trials to test investigational devices, recently performing the first pre-clinical and clinical studies to develop and perfect ablation catheters utilizing a novel, groundbreaking ablation energy source known as irreversible electroporation..

他一直并将继续参与许多首次人体试验以测试研究设备，最近进行了第一次临床前和临床研究，以开发和完善消融导管，利用一种新型的开创性消融能源，称为不可逆电穿孔。。

Burke T. Barrett, President and Chief Executive Officer of Pulse Biosciences concluded, “We are significantly strengthening our team with the addition of these renowned physicians who will contribute to generating high quality clinical data that demonstrates the clinical performance profile of the 360 catheter.

Pulse Biosciences总裁兼首席执行官伯克·巴雷特（Burke T.Barrett）总结道：“我们正在大力加强我们的团队，这些著名的医生将有助于产生高质量的临床数据，证明360导管的临床性能。

I want to thank Drs. Reddy and Koruth for their significant contributions in the pre-clinical and clinical evaluations of the 360 catheter to date.”.

我要感谢Reddy博士和Koruth博士迄今为止在360导管的临床前和临床评估中做出的重大贡献。”。

About Pulse Biosciences®

关于Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue.

Pulse Biosciences是一家致力于健康创新的新型生物电医学公司，有可能改善患者的生活质量。该公司专有的CellFX®nsPFA™技术为非热透明细胞提供纳秒级的电能脉冲，同时保留相邻的非细胞组织。

The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in Miami, Florida and maintains its office in Hayward, California..

该公司正在积极开发CellFX nsPFA技术，用于治疗心房颤动，并在其他一些特定市场中使用，这可能会对患者和提供者的医疗保健产生深远的积极影响。Pulse Biosciences目前总部位于佛罗里达州迈阿密，并在加利福尼亚州海沃德设有办事处。。

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Pulse Biosciences、CellFX、Nano Pulse Stimulation、NPS、nsPFA、CellFX nsPFA和程式化徽标是Pulse Biosciences，Inc.在美国和其他国家的商标和/或注册商标。

Pulse Biosciences宣布任命医学博士David Kenigsberg为电生理学首席医疗官

推荐资讯

从出汗看健康出汗透露你的健康信号

早上怎么喝水最健康？

Pulse Biosciences宣布任命医学博士David Kenigsberg为电生理学首席医疗官

推荐资讯

从出汗看健康 出汗透露你的健康信号

早上怎么喝水最健康？

从出汗看健康出汗透露你的健康信号